Allspring Global Investments Holdings LLC Sells 30,652 Shares of Repligen Corporation $RGEN

Allspring Global Investments Holdings LLC reduced its stake in Repligen Corporation (NASDAQ:RGEN) by 9.9% in the 1st quarter, Holdings Channel reports. The firm owned 280,523 shares of the biotechnology company’s stock after selling 30,652 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Repligen were worth $33,191,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of RGEN. Price T Rowe Associates Inc. MD boosted its holdings in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock valued at $753,603,000 after acquiring an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC bought a new position in Repligen during the third quarter worth $368,387,000. Opti Capital Management LP bought a new position in Repligen during the fourth quarter worth $2,399,209,000. Invesco Ltd. raised its stake in Repligen by 43.9% during the 4th quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after purchasing an additional 383,399 shares during the last quarter. Finally, Wasatch Advisors LP acquired a new position in Repligen during the 1st quarter valued at $146,513,000. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at approximately $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.60% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $147.25 on Monday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The stock has a market cap of $8.31 billion, a PE ratio of 163.61, a PEG ratio of 2.84 and a beta of 1.06. The business has a fifty day moving average of $128.69 and a two-hundred day moving average of $133.29. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The firm had revenue of $194.25 million for the quarter, compared to analyst estimates of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.39 earnings per share. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, equities research analysts expect that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on RGEN shares. Royal Bank Of Canada started coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price target for the company. Barclays upped their price target on Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Jefferies Financial Group restated a “hold” rating and set a $142.00 price objective on shares of Repligen in a research report on Tuesday, May 5th. Rothschild & Co Redburn set a $160.00 target price on Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Finally, Wolfe Research began coverage on shares of Repligen in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $165.00.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.